Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

1278 results about "Prostate" patented technology

The prostate (from Ancient Greek προστάτης, prostátēs, literally "one who stands before", "protector", "guardian") is an exocrine gland of the male reproductive system in most mammals. It differs considerably among species anatomically, chemically, and physiologically.

Systems and methods for automated screening and prognosis of cancer from whole-slide biopsy images

InactiveUS20140233826A1Accurate and unambiguous measureReduce dependenceImage enhancementMedical data miningFeature setProstate cancer
The invention provides systems and methods for detection, grading, scoring and tele-screening of cancerous lesions. A complete scheme for automated quantitative analysis and assessment of human and animal tissue images of several types of cancers is presented. Various aspects of the invention are directed to the detection, grading, prediction and staging of prostate cancer on serial sections/slides of prostate core images, or biopsy images. Accordingly, the invention includes a variety of sub-systems, which could be used separately or in conjunction to automatically grade cancerous regions. Each system utilizes a different approach with a different feature set. For instance, in the quantitative analysis, textural-based and morphology-based features may be extracted at image- and (or) object-levels from regions of interest. Additionally, the invention provides sub-systems and methods for accurate detection and mapping of disease in whole slide digitized images by extracting new features through integration of one or more of the above-mentioned classification systems. The invention also addresses the modeling, qualitative analysis and assessment of 3-D histopathology images which assist pathologists in visualization, evaluation and diagnosis of diseased tissue. Moreover, the invention includes systems and methods for the development of a tele-screening system in which the proposed computer-aided diagnosis (CAD) systems. In some embodiments, novel methods for image analysis (including edge detection, color mapping characterization and others) are provided for use prior to feature extraction in the proposed CAD systems.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

System and method of guided treatment within malignant prostate tissue

An imaging and diagnostic system and method are used for differentiating between malignant and non-malignant tissue of a prostate and surrounding region. The imaging device of the system acquires imaging data from the prostate and surrounding proximal region, processes the data to differentiate areas of tissue malignancy from non-malignant tissue. A sectioning device or ablative device is provided. The ablative device is operable by automation for receiving the imaging output coordinates and defining the trajectory and quantity of energy or power to be delivered into the malignant tissue of the prostate region. A control system determines calculated energy or power to be deposited into the malignant tissue during ablation, to minimize destruction of the non-malignant tissue within the prostate and surrounding tissue. The system operates on generated ablative device output data. In a second embodiment of the invention, the energy device output data guides the position or orientation of the delivery device or guides the delivery of energy or power from the ablative device into the malignant prostate tissue under active surveillance of the imaging device of the system. Destruction of the target tumor is thus monitored and controlled by active imaging.
Owner:TRACHTENBERG JOHN +2

Compositions and methods for the treatment of cancer

InactiveUS20020128228A1Reducing and avoiding adverse effectImprove toleranceBiocideAnimal repellantsIntestinal structureCancer prevention
This invention relates to compositions comprising temozolomide and thalidomide which can be used in the treatment or prevention of cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof. A particular composition comprises temozolomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof. The invention also relates to methods of treating or preventing cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof, which comprise the administration of temozolomide and thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of cancer chemotherapy or radiation therapy which comprise the administration of temozolomide and thalidomide to a patient in need of such reduction or avoidance.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Transcutaneous photodynamic treatment of targeted cells

The present invention is drawn to methods and compounds for photodynamic therapy (PDT) of a target tissue or compositions in a mammalian subject, using a light source that preferably transmits light to a treatment site transcutaneously. The method provides for administering to the subject a therapeutically effective amount of a targeted substance, which is either a targeted photosensitizing agent, or a photosensitizing agent delivery system, or a targeted prodrug. This targeted substance preferably selectively binds to the target tissue. Light at a wavelength or waveband corresponding to that which is absorbed by the targeted substance is then administered. The light intensity is relatively low, but a high total fluence is employed to ensure the activation of the targeted photosensitizing agent or targeted prodrug product. Transcutaneous PDT is useful in the treatment of specifically selected target tissues, such as vascular endothelial tissue, the abnormal vascular walls of tumors, solid tumors of the head and neck, tumors of the gastrointestinal tract, tumors of the liver, tumors of the breast, tumors of the prostate, tumors of the lung, nonsolid tumors, malignant cells of the hematopoietic and lymphoid tissue and other lesions in the vascular system or bone marrow, and tissue or cells related to autoimmune and inflammatory disease.
Owner:LIGHT SCI ONCOLOGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products